Dimension Therapeutics Announces Participation in Two Upcoming Investor Conferences
August 24 2016 - 7:00AM
Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical
company advancing novel, adeno-associated virus (AAV) gene
therapies targeting the liver, a key organ for human metabolism,
today announced that Dimension’s CEO Annalisa Jenkins, MBBS, MRCP,
will participate in two upcoming investor conferences:
- Citi's 11th Annual Biotech ConferencePanel:
Gene Therapy: A New EraWednesday, September 7, 2016 at 1:00 p.m.
Eastern TimeThe Mandarin Oriental Hotel, Boston, MA
- 2016 Wells Fargo Healthcare ConferenceFireside
Chat: Thursday, September 8, 2016 at 3:30 p.m. Eastern TimeThe
Westin Boston Waterfront Hotel, Boston, MA
Live audio webcasts of the presentations can be accessed through
the Investors section of the Company's website at
www.dimensiontx.com. Replays of the webcasts will be available on
the Company's website for two weeks following each
presentation.
About Dimension Therapeutics
Dimension Therapeutics, Inc. (NASDAQ:DMTX) is the leader in
discovering and developing new therapeutic products for people
living with devastating rare diseases associated with the liver,
based on the most advanced, mammalian adeno-associated virus (AAV)
gene delivery technology. Dimension is actively progressing its
broad pipeline, which features programs addressing unmet needs for
patients suffering from inherited metabolic diseases, including OTC
deficiency, GSDIa, citrullinemia type 1, PKU, Wilson disease, a
collaboration with Bayer in hemophilia A, and a wholly owned
clinical program in hemophilia B. The company targets diseases with
readily identifiable patient populations, highly predictive
preclinical models, and well-described, and often clinically
validated, biomarkers. Founded in 2013, Dimension maintains
headquarters in Cambridge, Massachusetts.
For more information, please visit
http://www.dimensiontx.com.
CONTACT:
Jean Franchi
Chief Financial Officer
Dimension Therapeutics
617-714-0709
jean.franchi@dimensiontx.com
Burns McClellan, on behalf of Dimension Therapeutics
Media: Justin Jackson
212-213-0006, ext.327
jjackson@burnsmc.com
DIMENSION THERAPEUTICS, INC. (NASDAQ:DMTX)
Historical Stock Chart
From Apr 2024 to May 2024
DIMENSION THERAPEUTICS, INC. (NASDAQ:DMTX)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Dimension Therapeutics, Inc. (NASDAQ): 0 recent articles
More News Articles